Global Medication Assisted Treatment Mat Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
8,191.94 Million
USD
16,808.38 Million
2021
2029
 Período de previsão |
2022 –2029 |
 Tamanho do mercado (ano base ) | USD 8,191.94 Million |
 Tamanho do mercado ( Ano de previsão) | USD 16,808.38 Million |
 CAGR |
% |
| Principais participantes do mercado |
Global Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others), Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029
Market Analysis and Insights
The Food and Drug Administration (FDA) approved three drugs for clinical use which are buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and by Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many medications considered essential to a functioning health care system.
The global medication-assisted treatment is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the medication-assisted (MAT) treatment market will grow at a CAGR of 9.4% during the forecast period of 2022 to 2029.
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2019 - 2014) |
|
Quantitative Units |
Revenue in USD Million, Pricing in USD |
|
Segments Covered |
By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others) |
|
Countries Covered |
By Country (U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa) |
|
Market Players Covered |
Indivior PLC, Orexo US Inc (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others. |
Market Definition
Medication-assisted treatment (MAT), involves the use of medications, combined with counselling and behavioural therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and grow in pregnancy outcomes among women.
Global Medication-Assisted (MAT) Treatment Market Dynamics
Drivers
- The Rise In Incidence Of Alcohol Use Disorder and Opioid Use Disorders
Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It encompasses the conditions that some people refer to as alcohol abuse, alcohol dependence, and alcohol addiction.
For instance,
- In 2022, the data by World Health Organization (WHO) European Region stated that alcohol disorder causes 1 million deaths annually
Medication-assisted treatment (MAT) is the use of medications in combination with counseling and behavioral therapies to provide a "whole-patient" approach to treating substance use disorders. Medications used in MAT are approved by the Food and Drug Administration (FDA), and MAT programs are clinically driven and tailored to meet each patient's needs.
- Use Of Reimbursement For Medication-Assisted Treatment (MAT)
Reimbursement may be available for medication-assisted treatment even if the medication does not have a valid status.
For instance,
- In February 2021, The American College of Emergency Physicians (ACEP) had developed the Reimbursement & Coding FAQs and Pearls for informational purposes on medication-assisted treatment
While, if the medication does not have preferred status, the prescriber must obtain permission from the member's pharmacy benefit plan.
Opportunities
- Rise In Healthcare Expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organizations will boost new opportunities for the market's growth rate.
For instance,
- In February 2021, according to Health Care Price Index (HCPI), the total U.S. healthcare budget had increased by 3.4%. The increase in growth states the federal government spending decreased significantly in the previous year from USD 287,000 million in 2020 to USD 170,000 million in 2021
Strategic Initiative By Market Players
The demand for medication-assisted treatment has increased in the U.S. and Europe due to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
For instance,
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.
Restraints/Challenges
- Side Effects Of Drugs Used In Medication-Assisted Treatment (MAT)
Medication-assisted treatment (MAT) involves using medications collated with counselling and behavioural therapies to provide a "whole-patient" approach as part of the comprehensive treatment strategy. MAT has been shown to be most effective for treating alcohol and opioid use disorders. However, certain side effects have been reported
For instance,
- Methadone and buprenorphine, the generic medications, are chemically similar to opioids, so their side effects can be similar too. These may include constipation, drowsiness, and dizziness. Some people may experience more severe side effects
Therefore, the present high cost is expected to show a descending trend.
- The Lack of Skilled Professionals, Required for Medication-Assisted Treatment
The lack or shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often the unemployed people in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to a lack of expertise.
For instance,
- In February 2021, according to NCBI, cultural barriers may include staff resistance to the use of medication-assisted treatment (MAT), a lack of perceived effectiveness of MAT, and a lack of knowledge about how to implement MAT within their treatment setting. Furthermore, little is known about how patient characteristics may be related to organizational decisions regarding the implementation of MAT
The Medication-assisted (MAT) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
Covid-19 Impact on the Medication-Assisted (MAT) Treatment Market
During the pandemic, medication-assisted treatment remarkably reduces mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for medication-assisted treatment in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during Covid-19 Medication for opioid use disorder (MOUD) services are key to addressing the opioid crisis, and COVID-19 has significantly impacted MOUD delivery.
Recent Development
- In April 2021, Adamis Pharmaceuticals Corporation with USWM announced the launch and availability of a high-dose ZIMHI injectable naloxone product to help combat opioid overdose deaths. The launch is expected to increase the product segment revenue, which will boost the market growth, and ZIMHI being made available at a discounted rate for first responders and community health organizations
Global Medication-Assisted Treatment (MAT) Market Scope
The medication-assisted (MAT) treatment market is segmented on the basis of eight segments: type, products, drug type, dosage form, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Medication
- Therapy
On the basis of type, the global medication-assisted (MAT) treatment market is segmented into medication and therapy.
Products
- Buprenorphine and Naloxone
- Naltrexone
- Buprenorphine
- Methadone
- Naloxone
- Disulfiram
- Acamprosate
On the basis of products, the global medication-assisted (MAT) treatment market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, methadone, naloxone, disulfiram and acamprosate.
Drug Type
- Generics
- Branded
On the basis of drug type, the global medication-assisted (MAT) treatment market is segmented into generics and branded.
Dosage Form
- Immediate Release
- Extended Release
On the basis of dosage form, the global medication-assisted (MAT) treatment market is segmented into immediate release and extended release.
Route of Administration
- Oral
- Parenteral
- Others
On the basis of route of administration, the global medication-assisted (MAT) treatment market is segmented into oral, parenteral and others.
Population Type
- Teenage
- Adults
On the basis of population type, the global medication-assisted (MAT) treatment market is segmented into adults and teenage.
End User
- Rehabilitation Clinics
- Hospitals
- Speciality Centers
- Homecare
- Others
On the basis of end user, the global medication-assisted (MAT) treatment market is segmented into rehabilitation clinics, hospitals, speciality centers, homecare and others.
Distribution Channel
- Hospital Pharmacy
- Direct Tender
- Retail Pharmacy
- Online Pharmacy
- Others
On the basis of distribution channel, the global medication-assisted (MAT) treatment market is segmented into hospital pharmacy, direct tender, retail pharmacy, online pharmacy and others
Medication-Assisted (MAT) Treatment Market Regional Analysis/Insights
The global medication-assisted (MAT) treatment market is analysed, and market size insights and trends are provided by regions, product type, application, workflow, end user and distribution channel. As referenced above.
The countries covered in the medication-assisted (MAT) treatment market report are the U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland, and Rest of Europe., China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, and the Rest of Middle East and Africa.
North America is expected to dominate the market due to a rise in the incidence of substance use disorders, ongoing clinical trials, and pharmaceutical companies.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future market trends. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Medication-Assisted (MAT) Treatment Market Share Analysis
The global medication-assisted (MAT) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, the Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the medication-assisted (MAT) treatment market.
Some of the major players operating in the medication-assisted (MAT) treatment market are Indivior PLC, Orexo US Inc. (a subsidiary of Orexo AB), Recovery Centers of America, Alkermes. Sun Pharmaceutical Industries Ltd., Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer Inc., Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical Inc. Viatris Inc., Mallinckrodt, Alvogen, Accord Healthcare, VistaPharm, Inc., Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. among others.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL
4.3 PORTER'S FIVE FORCES MODEL
4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)
4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)
4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)
4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)
4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET
5 GLOBAL MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS
6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)
6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)
6.2 RESTRAINTS
6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)
6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)
6.2.3 RISE IN PRODUCT RECALLS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
6.3.2 RISE IN HEALTHCARE EXPENDITURE
6.4 CHALLENGES
6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT
6.4.2 STRINGENT REGULATIONS
6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)
7 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 OPIOID DEPENDENCY MEDICATION
7.2.1.1 BUPRENORPHINE AND NALOXONE
7.2.1.2 BUPRENORPHINE
7.2.1.3 METHADONE
7.2.1.4 NALTREXONE
7.2.2 ALCOHOL USE DISORDER MEDICATIONS
7.2.2.1 NALTREXONE
7.2.2.2 DISULFIRAM
7.2.2.3 ACAMPROSATE
7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION
7.2.3.1 NALOXONE
7.3 THERAPY
7.3.1 BEHAVIORAL THERAPY
7.3.2 EDUCATIONAL THERAPY
7.3.3 COUNSELLING
7.3.4 VOCATIONAL THERAPY
7.3.5 OTHERS
8 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS
8.1 OVERVIEW
8.2 BUPRENORPHINE AND NALOXONE
8.3 NALTREXONE
8.4 BUPRENORPHINE
8.5 METHADONE
8.6 NALOXONE
8.7 DISULFIRAM
8.8 ACAMPROSATE
9 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 GENERICS
9.3 BRANDED
9.3.1 SUBOXONE
9.3.2 VIVITROL
9.3.3 BUTRANS
9.3.4 ZUBSOLV
9.3.5 PROBUPHINE
9.3.6 OTHERS
10 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM
10.1 OVERVIEW
10.2 IMMEDIATE RELEASE
10.3 EXTENDED RELEASE
11 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 SUBLINGUAL FILM
11.2.3 OTHERS
11.3 PARENTERAL
11.3.1 SOLUTION
11.3.2 SUSPENSION
11.4 OTHERS
12 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE
12.1 OVERVIEW
12.2 ADULTS
12.3 TEENAGE
13 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER
13.1 OVERVIEW
13.2 REHABILITATION CLINICS
13.3 HOSPITALS
13.4 SPECIALTY CENTERS
13.5 HOMECARE
13.6 OTHERS
14 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 DIRECT TENDER
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 FRANCE
15.3.3 U.K.
15.3.4 ITALY
15.3.5 RUSSIA
15.3.6 SPAIN
15.3.7 NETHERLANDS
15.3.8 SWITZERLAND
15.3.9 NORWAY
15.3.10 POLAND
15.3.11 HUNGARY
15.3.12 LITHUANIA
15.3.13 AUSTRIA
15.3.14 IRELAND
15.3.15 TURKEY
15.3.16 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 CHINA
15.4.2 JAPAN
15.4.3 INDIA
15.4.4 AUSTRALIA
15.4.5 SOUTH KOREA
15.4.6 SINGAPORE
15.4.7 MALAYSIA
15.4.8 THAILAND
15.4.9 INDONESIA
15.4.10 PHILIPPINES
15.4.11 VIETNAM
15.4.12 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 BRAZIL
15.5.2 ARGENTINA
15.5.3 PERU
15.5.4 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 SAUDI ARABIA
15.6.3 U.A.E
15.6.4 ISRAEL
15.6.5 EGYPT
15.6.6 KUWAIT
15.6.7 REST OF MIDDLE EAST AND AFRICA
16 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
16.3 COMPANY SHARE ANALYSIS: EUROPE
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 INDIVOR PLC (2021)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 VIATRIS INC (2021)
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 ALKERMES (2021)
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PURDUE PHARMA L.P. (2021)
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENTS
18.7 PFIZER (2021)
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENTS
18.8 GLENMARK PHARMACEUTICAL INC (2021)
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENTS
18.9 DR. REDDY’S LABORATORIES LTD (2021)
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ALVOGEN (2021)
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENTS
18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENTS
18.13 AMNEAL PHARMACEUTICALS LLC (2021)
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENTS
18.14 AMERICAN ADDICTION CENTERS (2021)
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENTS
18.15 HIKMA PHARMACEUTICALS PLC (2021)
18.15.1 COMPANY SNAPSHOT
18.15.2 REVENUE ANALYSIS
18.15.3 PRODUCT PORTFOLIO
18.15.4 RECENT DEVELOPMENTS
18.16 LANNETT (2021)
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 MALLINCKRODT (2021)
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)
18.18.1 COMPANY SNAPSHOT
18.18.2 REVENUE ANALYSIS
18.18.3 PRODUCT PORTFOLIO
18.18.4 RECENT DEVELOPMENT
18.19 PINNACLE TREATMENT CENTERS
18.19.1 COMPANY SNAPSHOT
18.19.2 PRODUCT PORTFOLIO
18.19.3 RECENT DEVELOPMENT
18.2 RECOVERY CENTERS OF AMERICA
18.20.1 COMPANY SNAPSHOT
18.20.2 PRODUCT PORTFOLIO
18.20.3 RECENT DEVELOPMENTS
18.21 TAJ PHARMACEUTICALS LIMITED
18.21.1 COMPANY SNAPSHOT
18.21.2 PRODUCT PORTFOLIO
18.21.3 RECENT DEVELOPMENTS
18.22 TITAN PHARMACEUTICALS (2021)
18.22.1 COMPANY SNAPSHOT
18.22.2 REVENUE ANALYSIS
18.22.3 PRODUCT PORTFOLIO
18.22.4 RECENT DEVELOPMENTS
18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))
18.23.1 COMPANY SNAPSHOT
18.23.2 PRODUCT PORTFOLIO
18.23.3 RECENT DEVELOPMENTS
19 QUESTIONNAIRE
20 RELATED REPORTS
Lista de Tabela
TABELA 1 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 2 MERCADO GLOBAL DE MEDICAMENTOS NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 3 MERCADO GLOBAL DE MEDICAMENTOS NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 4 MERCADO GLOBAL DE MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 5 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 6 MERCADO GLOBAL DE MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIÓIDES NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 7 MERCADO GLOBAL DE TERAPIA EM TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 8 MERCADO GLOBAL DE TERAPIA EM TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 9 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR PRODUTOS, 2020-2029 (US$ MILHÕES)
TABELA 10 MERCADO GLOBAL DE BUPRENORFINA E NALOXONA NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 11 MERCADO GLOBAL DE NALTREXONA NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 12 MERCADO GLOBAL DE BUPRENORFINA NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 13 MERCADO GLOBAL DE METADONA EM TRATAMENTOS MEDICADOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 14 MERCADO GLOBAL DE NALOXONA NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 15 MERCADO GLOBAL DE DISULFIRAM NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 16 MERCADO GLOBAL DE ACAMPROSATO NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 17 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 18 MERCADO GLOBAL DE GENÉRICOS NO TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 19 MARCAS GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 20 MARCAS GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 21 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR FORMA FARMACÊUTICA, 2020-2029 (US$ MILHÕES)
TABELA 22 LIBERAÇÃO IMEDIATA GLOBAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 23 LIBERAÇÃO PROLONGADA GLOBAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 24 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 25 MERCADO GLOBAL DE TRATAMENTOS ORAL ASSISTIDOS POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 26 MERCADO GLOBAL DE MEDICAMENTOS ORAL ASSISTIDOS POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 27 MERCADO GLOBAL DE TERAPIA PARENTERAL EM TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 28 MERCADO GLOBAL DE TERAPIA PARENTERAL EM TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 29 OUTROS INDIVÍDUOS NO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 30 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 31: ADULTOS NO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 32 MERCADO GLOBAL DE ADOLESCENTES EM TRATAMENTO MEDICADO (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 33 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 34 CLÍNICAS DE REABILITAÇÃO GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 35 HOSPITAIS GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 36 CENTROS DE ESPECIALIDADES GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 37 MERCADO GLOBAL DE CUIDADOS DOMICILIARES EM TRATAMENTOS ASSISTIDOS POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 38 OUTROS INDIVÍDUOS NO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 39 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 40 FARMÁCIAS HOSPITALARES GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 41 LICITAÇÃO DIRETA GLOBAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 42 FARMÁCIAS DE VAREJO GLOBAIS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 43 MERCADO GLOBAL DE FARMÁCIAS ONLINE NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 44 OUTROS INDIVÍDUOS NO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 45 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR REGIÃO, 2020-2029 (US$ MILHÕES)
TABELA 46 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR PAÍS, 2020-2029 (US$ MILHÕES)
TABELA 47 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 48 MERCADO DE MEDICAMENTOS NA AMÉRICA DO NORTE NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 49 MERCADO DE MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NA AMÉRICA DO NORTE NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 50 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 51 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA AMÉRICA DO NORTE, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 52 MERCADO DE TERAPIA EM TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 53 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR PRODUTOS, 2020-2029 (US$ MILHÕES)
TABELA 54 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 55 MARCA DA AMÉRICA DO NORTE NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 56 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR FORMA FARMACÊUTICA, 2020-2029 (US$ MILHÕES)
TABELA 57 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 58 MERCADO DE MEDICAMENTOS ORAL NA AMÉRICA DO NORTE PARA TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 59 MERCADO DE TRATAMENTO PARENTERAL ASSISTIDO POR MEDICAMENTOS (MAT) NA AMÉRICA DO NORTE, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 60 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 61 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 62 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA AMÉRICA DO NORTE, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 63 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DOS EUA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 64 MEDICAMENTOS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 65 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 66 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 67 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 68 TERAPIA NOS EUA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 69 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR PRODUTOS, 2020-2029 (US$ MILHÕES)
TABELA 70 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 71 MARCAS AMERICANAS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 72 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR FORMA DE DOSAGEM, 2020-2029 (US$ MILHÕES)
TABELA 73 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 74 MERCADO DE TRATAMENTOS MEDICADOS ORAL (MAT) NOS EUA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 75 TERAPIA PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT) DOS EUA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 76 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 77 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 78 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NOS EUA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 79 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO CANADÁ, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 80 MERCADO DE MEDICAMENTOS NO CANADÁ NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 81 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO CANADÁ, POR TIPO, 2020-2029 (US$ MILHÕES)
TABLE 82 CANADA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 CANADA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 CANADA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 86 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 87 CANADA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 88 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 89 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 CANADA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 91 CANADA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 92 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 93 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 MEXICO MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 MEXICO OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 MEXICO ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 MEXICO OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 MEXICO THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 102 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 103 MEXICO BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 104 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 105 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 106 MEXICO ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 107 MEXICO PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 108 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 109 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 110 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 112 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 119 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 120 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 121 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 122 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 123 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 124 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 125 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 126 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 127 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 128 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 GERMANY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 GERMANY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 GERMANY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 GERMANY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 GERMANY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 135 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABELA 136 MARCA ALEMANHA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 137 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ALEMANHA, POR FORMA FARMACÊUTICA, 2020-2029 (MILHÕES DE DÓLARES AMERICANOS)
TABELA 138 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ALEMANHA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 139 MERCADO DE TRATAMENTO MEDICADO ORAL (MAT) NA ALEMANHA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 140 ALEMANHA TERAPIA PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 141 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ALEMANHA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 142 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ALEMANHA, POR USUÁRIO FINAL, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 143 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ALEMANHA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 144 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 145 FRANÇA MEDICAMENTOS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 146 FRANÇA MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 147 FRANÇA MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 148 FRANÇA MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 149 FRANÇA TERAPIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 150 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA FRANÇA, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 151 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 152 MARCA FRANÇA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 153 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR FORMA FARMACÊUTICA, 2020-2029 (MILHÕES DE DÓLARES AMERICANOS)
TABELA 154 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 155 FRANÇA MERCADO DE TRATAMENTO MEDICADO ORAL (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 156 FRANÇA PARENTERAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 157 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 158 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 159 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA FRANÇA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 160 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 161 MERCADO DE MEDICAMENTOS NO REINO UNIDO PARA TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 162 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NO REINO UNIDO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 163 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NO REINO UNIDO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 164 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NO REINO UNIDO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 165 TERAPIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 166 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 167 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 168 MARCAS DO REINO UNIDO NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 169 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR FORMA DE DOSAGEM, 2020-2029 (MILHÕES DE DÓLARES AMERICANOS)
TABELA 170 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 171 MERCADO DE TRATAMENTO ORAL ASSISTIDO POR MEDICAMENTOS (MAT) NO REINO UNIDO, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 172 TERAPIA PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT) NO REINO UNIDO, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 173 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR TIPO DE POPULAÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 174 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR USUÁRIO FINAL, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 175 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO REINO UNIDO, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 176 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ITÁLIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 177 MERCADO DE MEDICAMENTOS NA ITÁLIA NO TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 178 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ITÁLIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 179 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ITÁLIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 180 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ITÁLIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 181 MERCADO DE TERAPIA EM TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ITÁLIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 182 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ITÁLIA, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 183 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ITÁLIA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 184 MARCA DA ITÁLIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 185 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ITÁLIA, POR FORMA FARMACÊUTICA, 2020-2029 (MILHÕES DE DÓLARES AMERICANOS)
TABELA 186 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ITÁLIA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 187 ITÁLIA MERCADO DE TRATAMENTO MEDICADO ORAL (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 188 ITÁLIA PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 189 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ITÁLIA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABLE 190 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 191 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 192 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 RUSSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 RUSSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 RUSSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 196 RUSSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 197 RUSSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 199 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 200 RUSSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 201 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 202 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 203 RUSSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 204 RUSSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 205 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 206 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 207 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 208 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 SPAIN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 SPAIN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 SPAIN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 SPAIN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 213 SPAIN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 215 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 216 SPAIN BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 217 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 218 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 219 SPAIN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 220 SPAIN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 221 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 222 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 223 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 224 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 225 NETHERLANDS MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 226 NETHERLANDS OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 227 NETHERLANDS ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 NETHERLANDS OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 229 NETHERLANDS THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 231 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 232 NETHERLANDS BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 233 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 234 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 235 NETHERLANDS ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 236 NETHERLANDS PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 237 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 238 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 239 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 240 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 241 SWITZERLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 SWITZERLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 SWITZERLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 SWITZERLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 SWITZERLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 247 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 248 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 249 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 250 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 251 SWITZERLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 252 SWITZERLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 253 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 254 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 255 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 256 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 NORWAY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 258 NORWAY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 NORWAY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 NORWAY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 NORWAY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 263 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 264 NORWAY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 265 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 266 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 267 NORWAY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 268 NORWAY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 269 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 270 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 271 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 272 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 POLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 POLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 POLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 POLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 277 POLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 278 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 279 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 280 POLAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 281 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 282 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 283 POLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 284 POLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 285 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 286 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 287 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 288 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 HUNGARY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 HUNGARY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 HUNGARY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 HUNGARY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 HUNGARY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 294 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 295 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 296 HUNGARY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 297 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 298 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 299 HUNGARY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 300 HUNGARY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 301 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 302 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 303 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 304 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 305 LITHUANIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 LITHUANIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 307 LITHUANIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 308 LITHUANIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 309 LITHUANIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 310 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 311 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 312 LITHUANIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 313 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 314 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 315 LITHUANIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 316 LITHUANIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 317 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 318 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 319 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 320 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 AUSTRIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABELA 322 ÁUSTRIA MEDICAMENTOS PARA DEPENDÊNCIA DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 323 ÁUSTRIA MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 324 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ÁUSTRIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 325 ÁUSTRIA TERAPIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 326 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 327 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 328 MARCA ÁUSTRIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 329 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR FORMA FARMACÊUTICA, 2020-2029 (US$ MILHÕES)
TABELA 330 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 331 ÁUSTRIA MERCADO DE TRATAMENTO ORAL ASSISTIDO POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 332 ÁUSTRIA PARENTERAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 333 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 334 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 335 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁUSTRIA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 336 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 337 MEDICAMENTOS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 338 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 339 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 340 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 341 TERAPIA NA IRLANDA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 342 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 343 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 344 MARCA DA IRLANDA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 345 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR FORMA DE DOSAGEM, 2020-2029 (MILHÕES DE DÓLARES AMERICANOS)
TABELA 346 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 347 MERCADO DE TRATAMENTO ORAL ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 348 IRLANDA PARENTERAL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 349 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 350 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR USUÁRIO FINAL, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 351 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA IRLANDA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 352 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 353 MEDICAMENTOS NA TURQUIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 354 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NA TURQUIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 355 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NA TURQUIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 356 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 357 TERAPIA DE PERU NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 358 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA TURQUIA, POR PRODUTOS, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 359 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 360 MARCA TURQUIA NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 361 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR FORMA DE DOSAGEM, 2020-2029 (US$ MILHÕES)
TABELA 362 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 363 TURQUIA ORAL NO MERCADO DE TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 364 TERAPIA PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 365 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 366 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA TURQUIA, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 367 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA TURQUIA, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 368 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NO RESTO DA EUROPA, POR TIPO, 2020-2029 (MILHÕES DE DÓLARES)
TABELA 369 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁSIA-PACÍFICO, POR PAÍS, 2020-2029 (US$ MILHÕES)
TABELA 370 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁSIA-PACÍFICO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 371 MEDICAMENTOS NA ÁSIA-PACÍFICO NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 372 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIÓIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DA ÁSIA-PACÍFICO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 373 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NA ÁSIA-PACÍFICO, POR TIPO, 2020-2029 (US$ MILHÕES)
TABLE 374 ASIA-PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 375 ASIA-PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 376 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 377 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 378 ASIA-PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 379 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 380 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 381 ASIA-PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 382 ASIA-PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 383 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 384 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 385 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 386 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 387 CHINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 388 CHINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 389 CHINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 390 CHINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 391 CHINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 392 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 393 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 394 CHINA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 395 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 396 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 397 CHINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 398 CHINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 399 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 400 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 401 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 402 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 403 JAPAN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 404 JAPAN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 405 JAPAN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 406 JAPAN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 407 JAPAN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 408 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 409 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 410 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 411 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 412 JAPAN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 413 JAPAN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 414 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 415 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 416 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 417 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 418 INDIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 419 INDIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 420 INDIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 421 INDIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 422 INDIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 423 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 424 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 425 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 426 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 427 INDIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 428 INDIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 429 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 430 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 431 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 432 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 433 AUSTRALIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 434 AUSTRALIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 435 AUSTRALIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 436 AUSTRALIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 437 AUSTRALIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 438 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 439 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 440 AUSTRALIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 441 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 442 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 443 AUSTRALIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 444 AUSTRALIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 445 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 446 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 447 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 448 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 449 SOUTH KOREA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 450 SOUTH KOREA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 451 SOUTH KOREA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 452 SOUTH KOREA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 453 SOUTH KOREA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 454 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 455 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 456 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 457 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 458 SOUTH KOREA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 459 SOUTH KOREA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 460 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 461 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 462 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 463 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 464 SINGAPORE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 465 SINGAPORE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 466 SINGAPORE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 467 SINGAPORE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 468 SINGAPORE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 469 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 470 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 471 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 472 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 473 SINGAPORE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 474 SINGAPORE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 475 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 476 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 477 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 478 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 479 MALAYSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 480 MALAYSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 481 MALAYSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 482 MALAYSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 483 MALAYSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 484 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 485 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 486 MALAYSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 487 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 488 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 489 MALAYSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 490 MALAYSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 491 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 492 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 493 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 494 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 495 THAILAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 496 THAILAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 497 THAILAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 498 THAILAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 499 THAILAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 500 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 501 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 502 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 503 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 504 THAILAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 505 THAILAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 506 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 507 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 508 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 509 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 510 INDONESIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 511 INDONESIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 512 INDONESIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 513 INDONESIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 514 INDONESIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 515 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 516 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 517 INDONESIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 518 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 519 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 520 INDONESIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 521 INDONESIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 522 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 523 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 524 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 525 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 526 PHILIPPINES MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 527 PHILIPPINES OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 528 PHILIPPINES ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 529 PHILIPPINES OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 530 PHILIPPINES THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 531 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 532 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 533 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 534 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 535 PHILIPPINES ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 536 PHILIPPINES PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 537 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 538 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 539 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 540 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 541 VIETNAM MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 542 VIETNAM OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 543 VIETNAM ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 544 VIETNAM OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 545 VIETNAM THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 546 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 547 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 548 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 549 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 550 VIETNAM ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 551 VIETNAM PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 552 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 553 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 554 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 555 REST OF ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 556 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 557 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 558 SOUTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 559 SOUTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 560 SOUTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 561 SOUTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 562 SOUTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 563 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 564 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 565 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 566 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 567 SOUTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 568 SOUTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 569 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 570 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 571 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 572 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 573 BRAZIL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 574 BRAZIL OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 575 BRAZIL ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 576 BRAZIL OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 577 BRAZIL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 578 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 579 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 580 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 581 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 582 BRAZIL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 583 BRAZIL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 584 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 585 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 586 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 587 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 588 ARGENTINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 589 ARGENTINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 590 ARGENTINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 591 ARGENTINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 592 ARGENTINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 593 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 594 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 595 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 596 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 597 ARGENTINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 598 ARGENTINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 599 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 600 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 601 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 602 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 603 PERU MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 604 PERU OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 605 PERU ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 606 PERU OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 607 PERU THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 608 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 609 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 610 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 611 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 612 PERU ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 613 PERU PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 614 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 615 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 616 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 617 REST OF SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 618 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 619 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 620 MIDDLE EAST AND AFRICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 621 MIDDLE EAST AND AFRICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 622 MIDDLE EAST AND AFRICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 623 MIDDLE EAST AND AFRICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 624 MIDDLE EAST AND AFRICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 625 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 626 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 627 MIDDLE EAST AND AFRICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 628 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 629 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 630 MIDDLE EAST AND AFRICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 631 MIDDLE EAST AND AFRICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 632 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 633 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 634 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 635 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 636 SOUTH AFRICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 637 SOUTH AFRICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 638 SOUTH AFRICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 639 SOUTH AFRICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 640 SOUTH AFRICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 641 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 642 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 643 SOUTH AFRICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 644 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 645 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 646 SOUTH AFRICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 647 SOUTH AFRICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 648 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 649 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 650 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 651 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 652 SAUDI ARABIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 653 SAUDI ARABIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 654 SAUDI ARABIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 655 SAUDI ARABIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 656 SAUDI ARABIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 657 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 658 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 659 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 660 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 661 SAUDI ARABIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 662 SAUDI ARABIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 663 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 664 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 665 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 666 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 667 U.A.E MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 668 U.A.E OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 669 U.A.E ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 670 U.A.E OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 671 U.A.E THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 672 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 673 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 674 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 675 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 676 U.A.E ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 677 U.A.E PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 678 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 679 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 680 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 681 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 682 ISRAEL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 683 ISRAEL OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 684 ISRAEL ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 685 ISRAEL OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 686 ISRAEL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 687 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 688 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 689 ISRAEL BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 690 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 691 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 692 ISRAEL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 693 ISRAEL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 694 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 695 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 696 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 697 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 698 EGYPT MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 699 EGYPT OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 700 EGYPT ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 701 EGYPT OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 702 EGYPT THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 703 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)
TABLE 704 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 705 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 706 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 707 EGYPT ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 708 EGYPT PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 709 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 710 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 711 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABELA 712 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 713 MEDICAMENTOS NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 714 MEDICAMENTOS PARA DEPENDÊNCIA DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 715 MEDICAMENTOS PARA TRANSTORNOS POR USO DE ÁLCOOL NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 716 MEDICAMENTOS PARA PREVENÇÃO DE OVERDOSE DE OPIOIDES NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 717 TERAPIA DO KUWAIT NO MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
TABELA 718 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR PRODUTOS, 2020-2029 (US$ MILHÕES)
TABELA 719 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO DE MEDICAMENTO, 2020-2029 (US$ MILHÕES)
TABELA 720 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR FORMA DE DOSAGEM, 2020-2029 (US$ MILHÕES)
TABELA 721 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 722 MERCADO DE TRATAMENTO ORAL ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 723 KUWAIT PARENTERAL NO MERCADO DE TRATAMENTO MEDICADO (MAT), POR VIA DE ADMINISTRAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 724 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR TIPO DE POPULAÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 725 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR USUÁRIO FINAL, 2020-2029 (US$ MILHÕES)
TABELA 726 MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DO KUWAIT, POR CANAL DE DISTRIBUIÇÃO, 2020-2029 (US$ MILHÕES)
TABELA 727 RESTANTE DO ORIENTE MÉDIO E ÁFRICA MERCADO DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT), POR TIPO, 2020-2029 (US$ MILHÕES)
Lista de Figura
FIGURA 1 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): SEGMENTAÇÃO
FIGURA 2 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): TRIANGULAÇÃO DE DADOS
FIGURA 3 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): ANÁLISE DROC
FIGURA 4 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): ANÁLISE DE MERCADO GLOBAL VS. REGIONAL
FIGURA 5 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): ANÁLISE DE PESQUISA DA EMPRESA
FIGURA 6 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): DEMOGRAFIA DA ENTREVISTA
FIGURA 7 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): GRADE DE POSIÇÃO DBMR
FIGURA 8 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): ANÁLISE DA PARTICIPAÇÃO DE FORNECEDORES
FIGURA 9 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): GRADE DE COBERTURA DO USUÁRIO FINAL
FIGURA 10 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): SEGMENTAÇÃO
FIGURA 11 A AMÉRICA DO NORTE DEVE DOMINA O MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) E A ÁSIA-PACÍFICO DEVE CRESCER COM O MAIOR CAGR NO PERÍODO DE PREVISÃO DE 2022 A 2029
FIGURA 12: AUMENTO DA INCIDÊNCIA DE TRANSTORNOS POR USO DE ÁLCOOL E AUMENTO NAS APROVAÇÕES DE PRODUTOS DEVEM IMPULSIONAR O MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DE 2022 A 2029
FIGURA 13 O SEGMENTO TIPO DEVE TER A MAIOR PARCIALIDADE DO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) DE 2022 A 2029
FIGURA 14 A AMÉRICA DO NORTE É O MERCADO DE CRESCIMENTO MAIS RÁPIDO E A ÁSIA-PACÍFICO DEVE CRESCER COM A MAIOR CAGR PARA FABRICANTES DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT) NO PERÍODO DE PREVISÃO DE 2022 A 2029
FIGURA 15 MOTIVADORES, RESTRIÇÕES, OPORTUNIDADES E DESAFIOS DO MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT)
FIGURA 16 INCIDÊNCIA DO CONSUMO DE ÁLCOOL EM 2019
FIGURA 17 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO, 2021
FIGURA 18 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO, 2022-2029 (US$ MILHÕES)
FIGURA 19 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO, CAGR (2022-2029)
FIGURA 20 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO, CURVA DE LINHA DE SALVAÇÃO
FIGURA 21 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR PRODUTOS, 2021
FIGURA 22 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): SUBPRODUTOS, 2022-2029 (US$ MILHÕES)
FIGURA 23 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): SUBPRODUTOS, CAGR (2022-2029)
FIGURA 24 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR PRODUTOS, CURVA DE LINHA DE SALVAÇÃO
FIGURA 25 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE MEDICAMENTO, 2021
FIGURA 26 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE MEDICAMENTO, 2022-2029 (US$ MILHÕES)
FIGURA 27 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE MEDICAMENTO, CAGR (2022-2029)
FIGURA 28 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE MEDICAMENTO, CURVA DE LINHA DE SALVAÇÃO
FIGURA 29 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR FORMA FARMACÊUTICA, 2021
FIGURA 30 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR FORMA FARMACÊUTICA, 2022-2029 (US$ MILHÕES)
FIGURA 31 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR FORMA FARMACÊUTICA, CAGR (2022-2029)
FIGURA 32 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR FORMA FARMACÊUTICA, CURVA DE LINHA DE SALVAÇÃO
FIGURA 33 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR VIA DE ADMINISTRAÇÃO, 2021
FIGURA 34 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR VIA DE ADMINISTRAÇÃO, 2022-2029 (US$ MILHÕES)
FIGURA 35 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR VIA DE ADMINISTRAÇÃO, CAGR (2022-2029)
FIGURA 36 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR VIA DE ADMINISTRAÇÃO, CURVA DA LINHA DE SALVAÇÃO
FIGURA 37 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE POPULAÇÃO, 2021
FIGURA 38 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE POPULAÇÃO, 2022-2029 (US$ MILHÕES)
FIGURA 39 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE POPULAÇÃO, CAGR (2022-2029)
FIGURA 40 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR TIPO DE POPULAÇÃO, CURVA DE LINHA DE SALVAÇÃO
FIGURA 41 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR USUÁRIO FINAL, 2021
FIGURA 42 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR USUÁRIO FINAL, 2022-2029 (US$ MILHÕES)
FIGURA 43 MERCADO GLOBAL DE TRATAMENTO ASSISTIDO POR MEDICAMENTOS (MAT): POR USUÁRIO FINAL, CAGR (2022-2029)
FIGURE 44 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE
FIGURE 45 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 46 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 47 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 48 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 49 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 50 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2021)
FIGURE 51 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2022 & 2029)
FIGURE 52 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2021 & 2029)
FIGURE 53 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 54 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 55 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 57 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 58 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 59 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 60 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 61 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 62 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 63 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 64 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 65 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 66 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 67 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 68 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 69 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 70 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 71 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 72 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 73 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 74 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)
FIGURE 75 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)
FIGURE 76 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)
FIGURE 77 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)
FIGURE 78 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)
FIGURE 79 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
FIGURE 80 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
FIGURE 81 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
FIGURE 82 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
